Navigation Links
Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Date:4/21/2009

SEATTLE, April 21 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the Company has enrolled the first patient in a Phase 1 clinical trial of D3263 in patients with advanced cancer. D3263 is Dendreon's lead small molecule drug candidate designed to target TRPM8 (a transmembrane cation channel protein) in cancer cells and induce cell death. The trial is an open-label, dose-escalation study evaluating the safety and pharmacokinetics of orally-administered D3263 in patients with solid tumors that are refractory to standard therapies.

The Phase 1 trial will enroll three to six patients per cohort during the dose escalation phase of the study. An expansion cohort may be enrolled following determination of the maximum tolerated dose. The primary endpoint of the study will be safety, but patients also will be evaluated for anti-tumor activity as well as tolerance of the drug in order to determine the optimal schedule and level of dosing. The trial has been initiated at South Texas Accelerated Research Therapeutics (START) in San Antonio Texas under the direction of Dr. Anthony W. Tolcher.

"D3263 is a drug candidate that has potential applicability to multiple types of cancer as well as to benign prostatic hyperplasia (BPH)," stated Mark Frohlich, M.D., senior vice president of clinical affairs and chief medical officer of Dendreon. "The ability of D3263 to inhibit growth of TRPM8 expressing tumors in preclinical studies coupled with its oral bioavailability make it an appealing product candidate to advance into human clinical trials."

Patients interested in additional information about this trial may visit www.clinicaltrials.gov and use the search term "D3263."

About TRPM8

TRPM8 (also known a
'/>"/>

SOURCE Dendreon Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Research and Markets( http://www.researchandmarkets.com/research/28m7nx/guide_to_prepare ) has ... Prepare Application Dossiers for Oversea Medical device registration ... report to their offering. The Chinese ... of the most growth potentiality, which is attracting ... producers to penetrate such market. It is estimated ...
(Date:5/22/2015)... 22, 2015 Richmond Pharmacology ... unit with a worldwide reputation for excellence in ... publications in peer reviewed medical journals. Its officers ... regulators in discussions about rules for transparency and ... (Logo: http://photos.prnewswire.com/prnh/20150522/745125) , Clinical research is ...
(Date:5/21/2015)... , May 21, 2015 ... announced the addition of the "North American ... Graft), by Application (Surgical Wound, & Ulcer), by ... to 2019" report to their offering. ,     ... care market is estimated to grow at a ...
Breaking Medicine Technology:China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 2China Guide to Prepare Application Dossiers for Oversea Medical Device Registration and Recordation 3North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... New results from the largest multicenter clinical trial for ... the International Society for Heart & Lung Transplantation (ISHLT) ...  Results show clinical benefit for the use of Everolimus ... 721 randomized patients at 67 medical centers spanning 5 ...
... April 14, 2011 Oxford Finance Corporation (Oxford), a ... a $2 million equipment loan with Synta Pharmaceuticals Corp. ... compounds for use in Synta,s ongoing clinical trials in ... "Synta Pharmaceuticals has a diverse drug pipeline, including ...
Cached Medicine Technology:Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 2Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 3Results From Largest Study of Anti-Rejection Therapy for Heart Transplant Patients Will be Released at ISHLT Meeting 4Oxford Finance Corporation Provides a $2 Million Equipment Facility to Synta Pharmaceuticals Corp. 2
(Date:5/25/2015)... San Rafael, CA (PRWEB) May 25, 2015 ... Field for a free two-hour instructional clinic. Irish National ... with campers and give them a taste of her coaching ... San Anselmo and Novato. Camps in Novato are at Lynwood ... 3). , Novato High School - June 6th, 2015 ...
(Date:5/25/2015)... May 25, 2015 Tunstall Americas announces ... the highest level of service to its Medical Answering ... and a restructuring of resources, Tunstall now provides a ... the Medical Answering Service to ensure superior patient satisfaction. ... it has invested over $10 million in expanded facilities ...
(Date:5/25/2015)... Dallas, TX (PRWEB) May 25, 2015 Decora ... renowned company ‘Leviton’ is now available on ‘The Hardware City.’ ... A user has to set a time and the related ... , When contacted a representative of the company said, “We ... ‘The Hardware City.’ Now customers can buy Countdown Timer Switch ...
(Date:5/24/2015)... May 24, 2015 The Rolling Stones ... 24th in San Diego at Petco Park. This iconic ... On May 20th, they had a warmup show in ... preview show in Los Angeles, this beloved band not only ... played fan favorites such as "Jumping Jack Flash," "Moonlight ...
(Date:5/24/2015)... May 24, 2015 For people who ... Chinese Enterokinase Industry, 2009-2019 Market Research Report would be ... an exhaustive study on the present market scenario of ... into the growing Chinese market of this industry. The ... overall status of the manufacturers in this industry. The ...
Breaking Medicine News(10 mins):Health News:US Sports Camps and Nike Soccer Camps Offer Complimentary Instructional Clinic with Fiona's Soccer Camp 2Health News:Tunstall Introduces New Medical Answering Service for the 21st Century Practice 2Health News:Leviton's Decora 60 Minute Countdown Timer Available On ‘The Hardware City’ 2Health News:The Rolling Stones Tickets in San Diego, Orlando, Minneapolis, Dallas, Pittsburgh, Indianapolis, Atlanta, Detroit, Milwaukee, Kansas City, Columbus, Nashville & Raleigh 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 2Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 3Health News:Global and Chinese Enterokinase Industry 2009-2019 Market Research Report Now Available at RnRMarketResearch.com 4
... New Accounts Sign On; Existing Accounts Expand , , ... practice management, announces impressive growth in the first quarter of ... addition to customer add-ons continues to drive Ingenious Med,s success ... Med originated as a company dedicated to hospitalist revenue-cycle, but ...
... , , Group led by conservative political ... , WASHINGTON, June 1 Public Campaign Action Fund issued ... Care Ads" to expose the group behind the political ads ... reform. The ads are funded by the Americans for Prosperity ...
... , MONDAY, June 1 (HealthDay News) -- Putting patients ... frequent detection of precancerous polyps than merely making patients ... colonoscopy, patients can either be put to sleep under ... which allows them to hear and respond to directions ...
... 1 ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... and Drug Administration (FDA) that the Dermatologic and Ophthalmic Drugs ... Bepreve(TM) (bepotastine ophthalmic solution) on June 26, 2009. , ... its NDA with the FDA for Bepreve as an eye ...
... New Web-based community will increase collaboration and resource-sharing in ... YORK, June 1 The Michael J. Fox Foundation ... Research ( pdonlineresearch.org ), a resource-rich virtual workplace that ... PD researchers and funders collaborating and conversing across the ...
... other name is still a rose, but is an ... ,jock, are sometimes used interchangeably, but they are really ... Buffalo researcher Kathleen E. Miller, Ph.D. "In terms of ... these two identities represent very different perspectives and may ...
Cached Medicine News:Health News:Ingenious Med Experiences Impressive Growth in First Quarter 2009 2Health News:Ingenious Med Experiences Impressive Growth in First Quarter 2009 3Health News:"Viewers Beware" Report by Watchdog Group Exposes Conservative Group Behind Anti-Healthcare Ads Running in Indiana 2Health News:Deep Sleep May Improve Colonoscopy Results 2Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 2Health News:ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis 3Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 2Health News:Michael J. Fox Foundation Announces Launch of PD Online Research 3Health News:Don't mistake an athlete for a 'toxic jock' 2
... The new DeVilbiss PulmoAide Compact Compressor provides effective ... size allows for therapy at home or on ... 5-year warranty, and the same reliable operation you ... ,The PulmoAide Compact Compressor is the perfect solution ...
The 16 liter Laparoscopy Insufflator combines high safety and precise pressure control with simple operation....
Stryker's 40-liter insufflator provides superior performance with unprecedented safety and reliability....
ACMI™ COAG Bipolar Laparoscopy Probes provide 360 of hemostatis, bipolar safety, blunt dissection, irrigation, and suction in one instrument....
Medicine Products: